Regenerative Medical Technology (RMTG) EBITDA Margin (2018 - 2026)
Regenerative Medical Technology (RMTG) posted EBITDA Margin of 15.72% for Q2 2026, up 36.9% on a QoQ basis from 11.48% in Q1 2026, and up 3806.0% year-over-year from 0.4% in Q2 2025.
Powered by 
Analysis
Regenerative Medical Technology (RMTG) EBITDA Margin (2018 - 2026) Analysis & Trends
Regenerative Medical Technology has reported EBITDA Margin for 9 years, with the latest figure at 15.72% in Q2 2026.
- On a quarterly basis, EBITDA Margin rose 3806.0% year-over-year to 15.72% in Q2 2026; TTM through Jun 2026 was 3.28%, a 405.0% decrease from a year earlier, with the FY2025 full-year figure at 13.4%, down 1838.0% from the prior year.
- EBITDA Margin was 15.72% for Q2 2026 at Regenerative Medical Technology, up from 11.48% in the prior quarter.
- The five-year high for EBITDA Margin was 21.74% in Q4 2024, with the low at 442.12% in Q4 2022.
- Average EBITDA Margin over 5 years is 50.07%, with a median of 12.47% recorded in 2023.
- The largest YoY upside for EBITDA Margin was 542147 bps in 2022 against a maximum downside of 25614 bps in 2022.
- Over 5 years, EBITDA Margin stood at 442.12% in 2022, then surged by 98 bps to 10.16% in 2023, then surged by 314 bps to 21.74% in 2024, then tumbled by 168 bps to 14.78% in 2025, then soared by 206 bps to 15.72% in 2026.
- The last three EBITDA Margin figures came in at 15.72% (Q2 2026), 11.48% (Q1 2026), and 14.78% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.22 Bn | 9.37 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.66 Bn | 3.36 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | -25,827.14% |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 1.95 Bn | 1.78 Bn | 56.40 Mn | 0.56% |
| 10 | Regenerative Medical Technology | 1.18 Mn | -139,694.93 | 2.58 Mn | 15.72% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.72% |
| Mar 31, 2026 | 11.48% |
| Dec 31, 2025 | -14.78% |
| Sep 30, 2025 | -33.38% |
| Jun 30, 2025 | -22.34% |
| Mar 31, 2025 | 11.90% |
| Dec 31, 2024 | 21.74% |
| Sep 30, 2024 | 8.53% |
| Jun 30, 2024 | -19.59% |
| Mar 31, 2024 | -6.48% |
| Dec 31, 2023 | -10.16% |
| Sep 30, 2023 | 3.65% |
| Jun 30, 2023 | -103.21% |
| Mar 31, 2023 | -5.34% |
| Dec 31, 2022 | -442.12% |
| Sep 30, 2022 | -33.17% |
| Jun 30, 2022 | -111.08% |
| Mar 31, 2022 | -172.59% |
| Dec 31, 2021 | -185.98% |
| Sep 30, 2021 | -5,454.64% |